Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Chief Legal Officer | August 06, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,324 |
Last balance in matching sequence
After 2026-08-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-06 · Exercise / conversion · Acquired 5,000 · Balance 57,324 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. F2: Includes 151 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2026. Row 2 · 2026-08-06 · Sale · Disposed 5,000 · Balance 52,324 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. F2: Includes 151 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.69 · Expires 2032-02-07 | Direct | 49,804 |
Reported balance
After 2026-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-06 · Exercise / conversion · Disposed 5,000 · Balance 49,804 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. F3: The shares underlying this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
F2: Includes 151 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2026.
F3: The shares underlying this option are fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2022 Filed Jan 3, 2023 22:10 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 28,770 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000307 · doc4.xml · derivative · entry 1 Khara Rahul · CIK 0001951850 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,770 Underlying: Common Stock · 28,770 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.